BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

QuantuMDx Group Acquires Identity Testing Specialist NorthGene to Expand Commercial DNA Analysis Portfolio


3/1/2013 11:31:13 AM

Newcastle, UK, March 4, 2013: QuantuMDx Group Limited, a leading UK medical devices company, today announced it hasacquired the entire share capital of commercial identity testing specialistNorthGene Limited in a transaction involving a share swap plus cash investment. Founded in 1995, NorthGene has established a worldwide reputation as a provider of identity testing services to not only the NHS, but also the legal profession and general public. The funds will be utilised to further develop NorthGene’s laboratory and staffing infrastructure, secure various laboratory accreditations and to expand the Company’s existing test portfolio and DNA analysis services to embrace medical, veterinary and scientific research applications.

NorthGene has historically been run as a not for profit organisation under the leadership of Sir John Burn, Professor ofClinical Genetics at Newcastle University, with all revenues invested back into medical research. Elaine Warburton, QuantuMDx’s CEO says “We have two main aims. Firstly to continue this philanthropic philosophy of using NorthGene surpluses to invest in advancing medical research for the benefit of globalhealth. Secondly for NorthGene to play a key role in the testing and the commercial roll-out of our ground-breaking diagnostic and sequencing devices which are now close to market.”

NorthGene’s Managing Director MarieWhitehouse comments “ With over 50% of our business overseas already and demand continuing to grow, this is a wonderful opportunity for NorthGene to further expand our test portfolio. QuantuMDx’s scientific, quality and commercial teams have access to, and extensive knowledge of, the very latest proven DNA based tests across medical and non-medical applications.”

NorthGene Limited

Contact

Marie Whitehouse, Managing Director

marie.whitehouse@quantumdx.com

Tel: +44 (0) 870 803 1234

Mob: + 44 (0) 78675 531 432

www.northgene.co.uk


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->